1800 244 735

Helpline (02) 9874 9777

Liver changes in Huntington's disease patients suggest more 'whole body' research needed

Huntington’s disease patients seem to have a lot of changes outside the brain, but these issues haven’t yet been studied in great detail. New evidence reveals that Huntington’s Disease mutation carriers have differences in liver function, even before they have symptoms of HD. This new finding might help us understand the metabolic changes experienced by HD patients, which are currently poorly understood and under-studied.

HD is a brain disease, right?

Huntington’s disease is often described as a ‘neurodegenerative’ disease. This just means that the main symptoms of the disease are thought to be caused by the early death of special brain cells called ‘neurons’.

Many of the most prominent symptoms of HD are almost certainly caused by the early death of neurons, including the noticeable movement symptoms that patients experience. It’s also likely that the problems with thinking and emotional regulation that make HD so difficult are also due to dead or dysfunctional brain cells.

Surprisingly, the mutant gene that causes HD is active, or transcribed, nearly everywhere in the body. When scientists first discovered the gene, they initially thought that it might only be made in vulnerable parts of the brain. In fact, it turned out that while only certain brain cells die during the course of HD, almost every cell in the body actively makes the HD gene.

In light of this widespread activity of the HD gene, it be surprising that scientists are really only just beginning to appreciate that things go wrong in HD patients outside the brain.

Some of these changes outside the brain are important for understanding the disease. At HDBuzz we’ve previously covered changes in the immune system of HD patients, while ‘calming down’ the immune system in HD mice makes them better, even when using drugs that don’t get to the brain!

Other aspects of Huntington’s disease are less well studied, but might be really important. Many HD patients lose weight, for example, even though they are eating sufficient calories. An early study of lifestyle factors suggested that HD patients who weighed more when they were first diagnosed with HD had a slower course of disease.

‘Metabolism’ is the term scientists use to describe all the chemical processes that enable our bodies to turn food into energy. Changes in metabolism leading to weight loss could have their origin in many different parts of the body – for example, the muscle, fat or liver. We’ve only just begun looking for changes in these other organs in Huntington’s disease patients.

Is the liver working less well in HD?

Many years ago, when physicians were first examining the organs of people who had died of Huntington’s disease, they noted that the livers seemed to be somewhat shrunken. Unlike brain cells, cells in the liver regenerate when they’re damaged. Cells in the liver of HD patients appear to be removed and replaced more quickly than in people without HD, which might mean that they’re experiencing more damage than normal.

Based in part on these observations, scientists have examined changes in the liver of mouse models of HD. Prof Jenny Morton, of the University of Cambridge, is particularly interested in changes in sleep in HD. As part of her studies in sleep, she’s studied which genes are turned off and on in the liver of HD mice over the course of a day. Mice, like humans, turn on different genes at different times of the day.

This complex regulation of turning specific genes on and off in the liver throughout the day doesn’t work right in HD mice. This could have major consequences for the metabolism of the whole body, because the liver plays a key role in metabolism.

Heavy, man

But are there changes in the liver in human Huntington’s disease patients? New evidence from a team of researchers led by Drs Carsten Saft and Sven Stüwe, in Bochum, Germany, suggests that there are.

The team did a very simple test of liver function in three groups of people: control subjects, people with the Huntington’s disease mutation but no symptoms of disease, and HD patients with symptoms. Each person drank a small amount of water that contained a chemical called methionine.

Methionine is one of the 21 ‘amino acid’ building blocks that our cells use to make all the proteins they need. So methionine naturally occurs in large amounts in the body.

The methionine provided by researchers was subtly different – they used methionine that had a abnormally heavy carbon atom. This gives each methionine molecule a different weight than normal, which lets the scientists use special equipment to track the heavy carbon drunk by the study subjects.

Why would they want to do this? It turns out that methionine that we drink or eat is only broken down in the liver, and the progress of this breakdown can be followed by looking for heavy carbon atoms in the carbon dioxide that patients exhale.

The test is very simple and pretty cool. Volunteers downed their amino acid drink, and exhaled into a machine capable of determining how much heavy carbon they were breathing out. But the implications are very important – many years of evidence suggest that we can accurately measure healthy liver function using this test.

HD patients exhaled less labeled carbon than control subjects did – a finding that suggests altered liver function. People carrying the HD mutation, but without symptoms of HD, also had less of the heavy carbon in their breath.

What does this mean?

This is the best evidence we yet have that liver function is altered in Huntington’s disease patients and people carrying the mutation. We also know that normal liver function is very important for regulating the metabolism of the entire body.

It’s important to note that these changes are subtle, and they don’t mean that people with the HD mutation have ‘liver disease’ or ‘liver failure’ – and there’s nothing to suggest that they are at increased risk of developing liver problems that could be risky in their own right.

We’re still a long way from understanding how liver changes might contribute to the changes we see in the metabolism of HD patients, but at least we now have a target to study. This finding is sure to give confidence to researchers interested in studying these types of changes, so look for more exciting ‘whole-body’ research in the future.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more